Background: Isolated tumor cells (ITC) are more likely to be identified when serial sectioning and immunohistochemical staining are used to evaluate sentinel lymph nodes (SLN). Our goal was to identify clinicopathologic features associated with ITC in patients undergoing sentinel lymph node dissection (SLND).
rately reflect the status of the regional nodal basin, thereby allowing for accurate staging of the axilla. [1] [2] [3] In fact, SLND has been shown to increase staging accuracy 4 and reduce false-negative rates 5 by allowing for a more detailed pathologic evaluation of a smaller number of lymph nodes that are at the highest risk of harboring metastatic disease.
During SLND, an average of three lymph nodes are recovered. 6, 7 Therefore, pathologists are able perform a more comprehensive examination of these SLNs than would be feasible for the larger number of lymph nodes recovered from a complete axillary lymph node dissection (CALND). This detailed examination includes the use of serial sectioning with hematoxylin and eosin (H&E) staining and may also include immunohistochemical (IHC) staining for cytokeratin. By means of these techniques, pathologists can detect microscopic deposits down to the level of isolated tumor cells (ITC) . In response to the increased use of SLND and the identification of microscopic foci of metastasis in lymph nodes, the most recent version of the American Joint Committee on Cancer (AJCC) staging system established definitions for lymph node involvement on the basis of the size of metastasis. 8 Definitions of macrometastasis (>2.0 mm), micrometastasis (>.2 to 2.0 mm), and ITC (£.2 mm) were established, and the pathologic categories pN1mi and pN0(i+) were added to indicate the presence of micrometastases or ITC. Lymph nodes that are negative for metastasis by both H&E staining and IHC are designated as pN0(i-). 8 Even though uniform criteria now distinguish ITC and micrometastases from macrometastases, debate remains over the clinical relevance of these smallvolume deposits in lymph nodes. Given the overall favorable prognosis of patients with early-stage breast cancer, the answer to this question will likely require multicenter trials that enroll large numbers of patients. Information from the American College of Surgeons Oncology Group (ACOSOG) Z0010 trial and the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-32 trial may help resolve questions regarding the impact of small-volume metastases in the SLN. [9] [10] [11] Both ACOSOG Z0010 and NSABP B-32 completed accrual in 2004. Longterm follow-up of these multicenter trials will be required to assess the prognostic significance of small-volume metastases.
Recognizing that long-term follow-up will be required to determine the effect of ITC on diseasefree survival (DFS) or overall survival (OS), we took a different approach in the current study to investigate the potential relevance of small-volume metastases. Our goal in this retrospective review was to determine if specific pathologic features known to have prognostic significance in breast cancer were associated with the presence of ITC in the SLNs of patients with early-stage disease undergoing SLND.
METHODS
The Institutional Review Board at the University of Texas M. D. Anderson Cancer Center approved this study. The study population was identified by a prospective database of patients undergoing intraoperative lymphatic mapping and SLND between November 1, 1993, and March 31, 2007. There were 3557 patients with invasive breast cancer and a clinically negative axilla by physical examination who had undergone SLND. A SLN was successfully identified in 3475 patients (97.7%) who made up the study population. Demographic data to include patient age and sex were noted. The following clinicopathologic data were recorded: biopsy method, primary tumor size (T stage), histologic subtype of the primary tumor, nuclear grade, presence or absence of lymphovascular invasion (LVI), estrogen receptor status, progesterone receptor status, and HER2/neu status. Biopsy methods included fineneedle aspiration biopsy, core biopsy, or excisional biopsy, which were either palpation guided or image guided. For hormone receptor status, we considered >10% positive staining of the cells by IHC to be positive. Tumors overexpressed HER2/neu if they were 3+ by IHC or positive by fluorescence in-situ hybridization.
We recorded the results of the SLND, including the number of SLNs removed, the number of positive SLNs, and the size of the metastasis for those SLNs that were positive. For patients who had undergone CALND, we also recorded the number of additional positive lymph nodes. We determined the status of all patients according to the 6th edition of the AJCC tumor, node, metastasis staging system.
Technique of Intraoperative Lymphatic Mapping and SLND
SLND was performed as previously described. 12, 13 Briefly, intraoperative lymphatic mapping was performed with a peritumoral injection of blue dye alone, 99m Tc-labeled sulfur colloid alone, or a combination of the two. When 99m Tc-labeled sulfur colloid was used, patients received filtered 99m Tc-labeled sulfur colloid injected peritumorally or into the parenchyma surrounding a biopsy cavity on the day before surgery (2.5 mCi) or on the day of surgery (.5 mCi). When blue dye was used, 5 mL of 1% isosulfan blue dye (Lymphazurin; US Surgical, Norwalk, CT) was injected into the breast parenchyma surrounding the tumor or biopsy cavity. For tumors that were not palpable, the injection was performed according to mammographic or sonographic guidance. In some cases, the surgeon injected the mapping agents into the subdermal or subareolar location. For patients who received 99m Tc-labeled sulfur colloid, a handheld gamma detection probe (NeoProbe 2000; US Surgical) was used intraoperatively to scan the axilla transcutaneously to identify the most radioactive area. An axillary incision was made over this hot spot, and SLNs were identified as nodes with uptake of blue dye, radioactive tracer, or both.
Pathologic Evaluation of the SLN
Pathologic evaluation of SLNs at our institution has evolved since we began performing the procedure in 1993. Before April 2000, SLNs were serially sectioned along the short axis at 2-to 3-mm intervals; sections were embedded in paraffin blocks, and one level from each block was stained with H&E. Beginning in April 2000, SLNs were grossly processed in the same manner, and each paraffin block was then serially sectioned at 5-lm intervals with two levels evaluated by routine H&E staining and one level analyzed for cytokeratin by IHC.
14 For this study, we identified all patients who had undergone SLND before April 2000 and had a histologically negative SLN. SLNs from these patients were reanalyzed by a senior breast pathologist (A.S.), who resectioned the paraffin blocks at 5-lm intervals. In addition to H&E staining, IHC was used to analyze one level for cytokeratin.
Statistical Analysis
Clinicopathologic factors were compared between groups by v 2 square analysis. Multivariate analysis was performed by ordered logistic regression. All analyses were performed by Stata software, release 10 (StataCorp, College Station, TX). A P value of <.05 was considered statistically significant. Table 1 details the clinicopathologic characteristics of 3475 patients with early-stage breast cancer and clinically negative axillary lymph nodes who underwent successful SLND. The median number of SLNs identified was 3 (range, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . The SLN had evidence of metastasis in 957 patients (27.5%), including 169 with ITC, 308 with micrometastasis, and 480 with macrometastasis.
RESULTS
For the 169 patients with ITC, the median number of SLNs removed was 3 (range, [1] [2] [3] [4] [5] [6] [7] [8] [9] , and the median number of SLNs with ITC present was one. Twentyfour patients had ITC identified in two SLNs, three patients had ITC identified in three SLNs, and one patient each had ITC identified in four and five SLNs. ITCs were identified by IHC only in 127 patients. We compared the group with a negative SLN and the group with ITC identified in the SLNs, and found no significant difference with respect to the method used to sample the primary tumor-fineneedle aspiration biopsy, core biopsy, or excisional biopsy (P = .10). Significant differences were seen with respect to specific tumor histologies (P = .003), with invasive lobular histology being significantly associated with ITC. A significant difference also existed between negative SLNs and SLNs with ITC with respect to the presence of LVI (P < .001) ( Table 2 , Fig. 1 ). Multivariate ordered logistic regression analysis determined that lobular histology and LVI were independently associated with an increased incidence of ITC (P < .001 for each factor).
CALND was performed in 890 patients, including 24 patients (14.2%) with ITC identified in their SLNs. Thirteen of these patients (54.2%) had ITC identified in their SLNs before implementation of the 6th edition of the AJCC staging system on January 1, 2003. After the AJCC staging system was revised, our institution's multidisciplinary group determined that patients with ITC identified in a SLN would be treated as having node-negative disease, consistent with their pN0(i+) designation. Therefore, a CAL-ND was not routinely performed. The 11 patients who underwent CALND after January 1, 2003, did so at the discretion of the attending surgeon, often because of other biologic factors such as primary tumor size (i.e., T2 or larger in seven patients). Additional nodal metastases were identified in four patients (16.7%) undergoing CALND after ITC were found in their SLNs. In all four patients, the additional metastases were macrometastases, resulting in upstaging from node-negative to node-positive disease.
Of 169 patients with ITC, 3 (1.8%) have experienced recurrence of disease. Median follow-up time for the whole group was 38 months. Median time to recurrence in the three patients mentioned above was 16 months (distant disease in two and locoregional [infraclavicular] in one). The patient with an infraclavicular recurrence was one of the patients who underwent CALND and was upstaged to pN1 disease. This patient had a 6-cm tumor that was negative for estrogen receptor, progesterone receptor, and HER2/neu, and she declined adjuvant chemotherapy. The three other patients found to have additional metastases at the time of CALND have not had evidence of recurrent disease.
Current AJCC criteria classify ITC (pN0[i+]) as node-negative disease and micrometastases (pN1mi) as node-positive disease. We were therefore interested in determining whether the same clinicopathologic features that were associated with ITC, which currently are considered node negative, would be associated with micrometastasis that are also considered small-volume disease but designated as node positive. We compared the group with negative SLN (pN0[i-]) and the group with micrometastasis (pN1mi) and found that there was no difference (P = .19) on the basis of the biopsy method used. Significant differences were again seen with respect to lobular histology (P = .007) and the presence of LVI (P < .001) ( Table 2 ). There was also a significant difference with respect to T stage, with micrometastasis more commonly seen in patients with T2 primary lesions ( ‡2 cm) (P < .001).
Having demonstrated that the presence of LVI was associated with an increased incidence of both ITC and micrometastasis in the SLNs of early-stage breast cancer patients, we investigated whether the presence of LVI affected SLN tumor burden, defined as the size of the metastasis. We found that an increasing SLN burden was associated with a greater likelihood of finding LVI in the primary tumor (Fig. 2) . LVI was found in the primary tumor of 8.5% (n = 213) of patients who were SLN negative, in 18.3% (n = 31) of patients with ITC, 26.3% (n = 81) with micrometastasis, and 33.8% (n = 162) with macrometastasis (P < .001). 
DISCUSSION
This study showed that the presence of LVI and lobular histology are greatly associated with detection of ITC and micrometastasis in SLNs in a large cohort of patients with early-stage breast cancer undergoing SLND. Importantly, with increasing SLN tumor burden, there was an increase in the percentage of patients with LVI in their primary tumor. Taken together, these data suggest that smallvolume metastasis may have biologic relevance in this patient population.
Most data available on the prognostic value of ITC and micrometastases come from older retrospective studies. In several early studies, patients with metastases 2.0 mm or smaller identified in complete axillary lymph node specimens by routine sectioning and H&E staining had no survival disadvantage when compared with patients with node-negative disease. [15] [16] [17] Additional studies have examined the impact of more rigorous pathologic examination, including serial sectioning and IHC staining for cytokeratin (Table 3) . In those studies, some investigators found that the presence of small-volume occult metastases negatively affected outcome, whereas others demonstrated no effect. [18] [19] [20] In a study that looked specifically at the relevance of ITC, Querzoli et al. 21 reviewed 702 patients from a single institution. Whole axillary dissection specimens were analyzed, and 377 cases identified as being pN0 were reevaluated by means of serial sectioning and IHC. After a median follow-up of 8 years, these authors found that ITC had a marked impact on event-free survival, with an unadjusted hazard ratio of 2.51 for pN0(i+) disease versus pN0(i-) disease (P < .001).
These earlier studies all analyzed CALND specimens. Few studies have addressed the prognostic significance of ITC or micrometastases identified in SLNs. Recently, two large single-institution series looked at the clinical significance of small-volume metastases. Hansen et al. 22 reported on 790 patients undergoing SLND at the John Wayne Cancer Center. Four hundred eighty-six patients (61.5%) were node negative, 84 (10.6%) had ITC, 54 (6.8%) had 23 reviewed 2381 patients found to have pN0(i-) (n = 2108), pN0(i+) (n = 151), or pN1mi (n = 122) disease on SLND. Patients with pN1mi disease had significantly worse DFS and OS than patients with pN0(i-) disease (P = .006 and P < .001, respectively). Disease-free and OS of patients with pN0(i+) disease were not markedly different than that of patients with pN0(i-) disease. 23 It is likely that several factors-including the use of adjuvant therapy, sample size, and length of followup-are responsible for the differences seen in these highlighted studies. For example, in the study from the John Wayne Cancer Institute, no difference in DFS or OS was demonstrated after a median followup of only 6 years. Although this follow-up would seem adequate for many breast cancer studies, we think it may not have been long enough to differentiate outcomes between patients with pN0(i-), pN0(i+), and pN1mi disease, who have very low rates of disease recurrence after administration of multimodality therapy.
The findings in the current study provide important information regarding these small-volume metastasis. It has been reported that identification of ITC in the SLN may not be due to lymphatic dissemination from the tumor but due to iatrogenic dislodgment after manipulations such as needling procedures to obtain tissue for diagnosis or pre-SLND breast massage. [24] [25] [26] In the current series of 169 patients with ITC, we have shown that biopsy method was not associated with the identification of these small-volume tumor deposits. This finding suggests that ITC are true malignant cells. These data emphasize the importance of an experienced breast pathologist interpreting the results of SLND, particularly when IHC is used.
Our finding that LVI is associated with the presence of ITC in the SLN suggests that small-volume metastases may be biologically relevant and therefore may ultimately be found to have prognostic significance. LVI has been demonstrated in many studies to be a poor prognostic factor in breast cancer. With respect to the effect of LVI on nodal metastasis, the presence of LVI has been shown to predict the presence of disease in four or more axillary lymph nodes. 32 In addition, our group previously reported that LVI independently predicts non-SLN involvement in patients with a positive SLN. 33 In a publication by Van Zee et al., 34 investigators at the Memorial Sloan Kettering Cancer Center also determined that LVI was predictive of identifying additional, non-SLN metastases in patients with a positive SLN. The presence of LVI was therefore incorporated into a what is now a widely used nomogram developed to predict non-SLN disease in patients with positive SLNs. Recently, a nomogram was published that predicts the likelihood that a patient with breast cancer will have a positive SLN. 35 On multivariate analysis used to construct that nomogram, LVI was associated with SLN metastasis. We identified a relationship between increased SLN tumor burden and an increased likelihood of finding LVI in the primary tumor. Only 8.5% of patients with node-negative (pN0[i-]) disease had LVI in the primary tumor, compared with 18.3% with ITC, 26.3% with micrometastases, and 33.8% with macrometastases. These data provide strong evidence that ITC are true metastases and of the significance of LVI in predicting the spread of tumor to the lymph nodes.
In this study, we also determined that lobular histology is associated with identifying ITC and micrometastasis. This finding is consistent with data reported by Cserni et al. 36 In a study reporting on a multi-institutional cohort of 449 patients with invasive lobular cancer staged by SLND, 189 patients (42%) were found to have nodal involvement, including 19 with ITC and 64 with micrometastasis. In most ITC cases (17 of 19, 90%) and micrometastases (40 of 64, 63%), IHC was required to identify disease after routine H&E staining yielded negative results. 36 A similar finding was recently published by Tan et al. 20 from the Memorial Sloan Kettering Cancer Center. These investigators reviewed records from 368 patients with axillary node-negative invasive breast cancer that had been treated with mastectomy and axillary dissection, but no systemic therapy. The investigators reexamined the axillary tissue blocks by serial sectioning and IHC and found that 83 patients (23%) had evidence of metastasis, including 61 (73%) with ITC and 17 (20%) with micrometastasis. They found a higher rate of occult metastasis in invasive lobular carcinoma (40%) than in invasive ductal carcinoma (20%), overrepresentation of lobular carcinoma among IHC-detected (36%) versus H&E-detected (15%) lesions, and overrepresentation of lobular carcinoma among patients with single-cell (59%) versus clustered metastases (7%).
The relationship between lobular histology and the presence of ITC is likely explained by the biology of invasive lobular cancer metastases, which are often noncohesive cells. 36 Metastases from lobular cancer therefore frequently manifest as small foci scattered throughout a lymph node, which can be difficult to detect with H&E staining. These data suggest that IHC staining for cytokeratin may be particularly important in the evaluation of SLNs from patients with lobular carcinoma. 20, 36 Taken together with data from the current study, these findings suggest that physicians should consider CALND in patients with lobular carcinoma who have ITC in their SLNs because the current pN0(i+) designation may understage disease in these patients if ITC represent true metastases in this histologic subtype.
Review of the literature suggests that there is no consensus as to the appropriate surgical management of the axilla in patients with ITC or micrometastases in the SLN. At the University of Texas M. D. Anderson Cancer Center, we have recommended CALND for patients with micrometastases, in accordance with AJCC criteria classifying these lesions as node-positive disease. Similarly, we have treated patients with only ITC in their SLNs as having node-negative disease, and we have not routinely performed further axillary surgery. 37 The results of the current study have caused us to reassess this approach. Despite the small number of patients in this study who had undergone CALND after identification of ITC, additional nodal disease was identified in approximately 17% of them, resulting in disease upstaging for these patients. This finding of additional metastasis in 17% is consistent with a study by Viale et al., 38 which reviewed the experience at the European Institute of Oncology and found additional metastases in 14.7% of patients with ITC in their SLNs. After evaluating these data together with the data from the current study, we now recommend performing CALND selectively in patients with ITC identified in their SLNs.
Metastases from lobular carcinoma frequently present as small foci scattered throughout a lymph node, which may only be seen as ITC. Therefore, we now recommend CALND for patients with lobular carcinoma who have ITC in the SLNs. The relationship between LVI and the presence of ITC is also interesting. LVI has clearly been demonstrated to be a poor prognostic factor in breast cancer, and the presence of LVI has influenced adjuvant systemic therapy decisions. 39 It is reasonable to consider the presence of LVI when recommending locoregional treatment. We are therefore considering a registry trial in which all patients with LVI and ITC would undergo CALND. Our goal is to further refine a profile of clinicopathologic features that will determine which patients with ITC identified in their SLNs will benefit from CALND.
